<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2013-10-19 18:07:33Biology Boceprevir Gilead Sciences Boehringer Ingelheim Interferon NS3 Pharmacology Microbiology Protease inhibitors Telaprevir Hepatitis C virus |
|
| First Page | Document Content | |
|---|---|---|
Date: 2013-10-19 18:07:33Biology Boceprevir Gilead Sciences Boehringer Ingelheim Interferon NS3 Pharmacology Microbiology Protease inhibitors Telaprevir Hepatitis C virus |
|
Clinical Nursing Experience with Direct Acting Antivirals (DAA’s) Montreal – Feb 24, 2012 Keri Earnshaw, RN, CCRP Jo-Ann Ford, RN, MSN BC Hepatitis Program